Quick read

Device lead-associated TR: why the team matters

A pacemaker or ICD lead crossing the tricuspid valve can cause TR — but lead presence alone does not establish causality. Learn the four lead-valve mechanisms, how 3D echo separates them from functional TR, and why device and valve teams decide together.

An echo report says 'possible lead impingement on the tricuspid leaflet.' Two questions follow. Is the lead actually part of the mechanism, or is this functional TR in a patient who happens to have a lead? And if the lead is involved, who decides what to do about it?

Key takeaway

Lead presence alone does not establish causality. Look for leaflet restriction, malcoaptation, and jet origin at the exact site of lead contact — and expect functional TR to coexist. When the lead is part of the mechanism, device and valve teams plan management together.

Key points

  • Lead presence alone does not establish causality. Assess lead position relative to the leaflets, systolic leaflet motion, coaptation, and jet origin.
  • Four lead-valve mechanisms: impingement, adhesion, perforation, and subvalvular interference.
  • Impingement and adhesion differ in diastole: with impingement the leaflet separates from the lead; with adhesion they move together throughout the cardiac cycle.
  • Mechanical lead interference and functional TR can coexist. A jet near the lead does not prove the lead caused it.
  • 3D echo shows which leaflet the lead touches and where the jet originates. TEE is an option when TTE windows are inadequate, not an automatic upgrade.
  • The TR Intervention Navigator routes to device-valve team evaluation once severe TR is confirmed. Clinically, consult earlier when symptoms progress or the RV is failing.

When to read this

Read this when a patient with a pacemaker or ICD has significant TR, especially when the echo report mentions leaflet restriction, a jet near the lead, or possible lead impingement.

How a lead can cause TR

Almost every transvenous RV lead crosses the tricuspid valve, and many patients with a lead have no significant TR. Lead presence alone does not establish causality. What matters is where the lead sits relative to the leaflets, how the leaflet moves in systole, whether coaptation fails at that site, and whether the jet originates there. The 2024 European Heart Journal review describes four lead-valve interactions:

  • Impingement — the lead and leaflet separate in diastole; in systole the closing leaflet meets the lead and its motion is restricted, leaving a coaptation defect at the contact site.
  • Adhesion — the lead and leaflet are stuck together and move together throughout the cardiac cycle; systolic leaflet excursion is restricted.
  • Perforation — the lead passes through the leaflet body, leaving a focal defect with regurgitation through it.
  • Subvalvular interference — the lead is caught in or presses on the chordae, so the leaflet cannot close properly.

These are typical imaging patterns. With limited image quality or combined lesions, impingement and adhesion cannot always be separated cleanly.

Echo clues: mechanical vs functional TR

FindingLead-related mechanical TRFunctional TR
Leaflet motionLocalized restriction at lead contactTethering or malcoaptation from chamber remodeling
Jet originMay originate at the lead-contact siteOften a broader coaptation gap
Annulus, RV, RADilation may or may not be presentAnnular dilation; RV dilation in ventricular functional TR, RA enlargement in atrial functional TR
3D echoShows lead-leaflet interactionShows annular dilation, tethering, and coaptation gap

Both mechanisms can be present

Mechanical lead interference and functional TR can coexist. Check for RV dilation, leaflet tethering, RA enlargement, and annular dilation even when the lead looks guilty. An eccentric jet, or a jet near the lead, does not prove the lead caused the TR.

What 3D echo adds

  • On 2D, the lead and the leaflets are often not in the same plane, so their relationship is easy to misjudge.
  • A 3D TTE en face view identifies the anterior, posterior, and septal leaflets and shows which one the lead touches.
  • Following the lead and leaflet through the cardiac cycle separates impingement from adhesion.
  • 3D color locates the coaptation defect and the jet origin, and shows whether they match the contact site.
  • When TTE windows are inadequate, consider 3D TEE and multiplanar reconstruction. TEE is not automatically better: the tricuspid valve lies far from the probe and lead shadowing can hide the leaflets.

Why device-valve team evaluation matters

The device team assesses lead type, dwell time, lead integrity, pacing dependence, extraction risk, and alternative pacing options. The valve team assesses integrated TR severity, leaflet and annular anatomy, RV function, and surgical or transcatheter options.

The decisions interlock. Removing a lead may not fix TR driven by RV or annular remodeling, and the chance of TR improving after extraction falls as time passes. A transcatheter tricuspid device can trap a lead that may later need to come out. That is why the plan is made jointly rather than by either team alone.

What the Navigator does — and does not do

  • The TR Severity Tool grades severity only. Mixed findings — for example a vena contracta of 0.7 cm with hepatic vein blunting rather than reversal — can return a discordant or indeterminate grade.
  • If severity is entered as uncertain or discordant, the TR Intervention Navigator returns 'confirm severity and mechanism first.'
  • Once severe TR is confirmed, a device lead mechanism (or a lead with suspected interference) routes to 'device-valve team evaluation.'
  • Neither tool recommends lead extraction, revision, repositioning, or a specific valve procedure.

The tool's branch point is not the referral threshold

The Navigator's 'severe TR confirmed' condition only decides which pathway it displays. With progressive symptoms, RV dysfunction, venous congestion, or suspected mechanical interference, you do not need to wait for the tool: consulting the device and valve teams early, in parallel with confirming severity, is reasonable. The 2024 EHJ review likewise calls for early referral to an expert center once significant tricuspid disease develops in a patient with a lead.

Related case

  1. Andreas M, Burri H, Prendergast B, et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J. 2024;45(5):346–365. doi:10.1093/eurheartj/ehad783
  2. Hahn RT, Wilkoff BL, Kodali S, et al. Managing Implanted Cardiac Electronic Devices in Patients With Severe Tricuspid Regurgitation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(20):2002–2014. doi:10.1016/j.jacc.2024.02.045
  3. Deharo JC, Dreyfus J, Bongiorni MG, et al. Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the EHRA and EAPCI of the ESC. Europace. 2025;euaf061. doi:10.1093/europace/euaf061
  4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25–e197.

Related valve learning

Apply this in practice

Once severe TR is confirmed, use the TR Intervention Navigator to see the pathway for device lead-associated TR.

Open TR Intervention Navigator